Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

被引：0
作者：
Katharina Götze
Uwe Platzbecker
Aristoteles Giagounidis
Detlef Haase
Michael Lübbert
Carlo Aul
Arnold Ganser
Ulrich Germing
Wolf-Karsten Hofmann
机构：
[1] Technische Universität München,III. Medizinische Klinik
[2] Universitätsklinikum Carl Gustav Carus,undefined
[3] St. Johannes Hospital,undefined
[4] Georg-August-Universität,undefined
[5] Albert-Ludwigs-Universität,undefined
[6] Medizinische Hochschule,undefined
[7] Heinrich-Heine-Universität,undefined
[8] Universitätsmedizin Mannheim,undefined
来源：
Annals of Hematology | 2010年 / 89卷
关键词：
Myelodysplastic syndromes; MDS; Azacitidine; Epigenetic therapy; Demethylating agents;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML). For many years, the main treatment option for MDS was best supportive care which alleviates symptoms, but has no effect on the natural course of the disease. Recently, demethylating agents have become available as a promising new treatment for patients with MDS. In two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, improvement of peripheral blood values, an improved quality of life, and a definite survival advantage compared to conventional care regimens for patients with International Prognostic Scoring System score of intermediate-2 or high-risk MDS. This review aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, assuring safe administration and best efficacy of treatment.
引用
收藏
页码：841 / 850
页数：9
相关论文
共 168 条
  • [1] Germing U(2008)Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes Ann Hematol 87 691-699
  • [2] Aul C(2008)Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs Blood 112 45-52
  • [3] Niemeyer CM(1997)International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079-2088
  • [4] Rollison DE(2005)Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 7594-7603
  • [5] Howlader N(2007)New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 4385-4395
  • [6] Smith MT(2001)Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS Blood 98 2326-2331
  • [7] Greenberg P(2003)Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia Ann Hematol 82 336-342
  • [8] Cox C(2004)Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Blood 104 1616-1623
  • [9] LeBeau MM(2009)Impact on survival of different treatments for myelodysplastic syndromes (MDS) Leuk Res 33 1024-1028
  • [10] Malcovati L(2002)Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2429-2440
12345678910